Overview

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
Otsuka America Pharmaceutical
Treatments:
Aripiprazole